tiprankstipranks
Advertisement
Advertisement
Madrigal Pharmaceuticals reports Q4 EPS ($2.57), consensus (88c)
PremiumThe FlyMadrigal Pharmaceuticals reports Q4 EPS ($2.57), consensus (88c)
2M ago
Paulson buys Solstice, exits Honeywell in Q4
Premium
The Fly
Paulson buys Solstice, exits Honeywell in Q4
2M ago
MDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
MDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed
PremiumWeekend UpdatesMadrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed
3M ago
Madrigal Pharmaceuticals price target raised to $745 from $527 at Citizens
Premium
The Fly
Madrigal Pharmaceuticals price target raised to $745 from $527 at Citizens
3M ago
Madrigal Pharmaceuticals price target raised to $644 from $554 at TD Cowen
Premium
The Fly
Madrigal Pharmaceuticals price target raised to $644 from $554 at TD Cowen
4M ago
Madrigal Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research
PremiumThe FlyMadrigal Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research
4M ago
These Are the Most and Least Likely Biotech Takeover Targets for 2026
Premium
Market News
These Are the Most and Least Likely Biotech Takeover Targets for 2026
4M ago
Short Report: Vera Therapeutics bears retreat as stock rallies
Premium
The Fly
Short Report: Vera Therapeutics bears retreat as stock rallies
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100